Covance

covance drug development clinical trials clinical development cro market access services clinical research phase iv drug development drug research clinical studies pharmaceutical market access pharmacovigilance biotechnology patient centricity case study pharma covance inc. drug development regulatory considerations drug studies gene therapy clinical trial optimization regulatory cell therapy healthcare biotech fda patient recruitment data biosimilars covance inc fspx preclinical crop protection drug safety drug trials risk management patient enrollment rwe real-world evidence send biomarkers reach chemical services inhalation studies phase i drug development bioanalysis safety assessment labcorp lifesciences gene replacement therapies biopharmaceutical analytical solutions pharmaceuticals study design nash preclinical development central laboratory services mass spectrometry patient safety pharmacovigilance outsourcing biotech development xcellerate medical devices patient support bio cmc patient insights solutions diabetes bioanalytical diagnostics development nonclinical development virtual scientific research covance fspx sciformix central labs antibodies clinical trial data cgmp clinical pharmacology medicine clinical trial technology patient access patient voice clinical (phase i - iii) nonclinical data covance market access pediatrics rare disease vaccine china immuno-oncology oncology solutions phase ii-iv pv strategy rheumatoid arthritis clinical testing drug development tools antibiotics recruitment marker access respiratory clinical development biologics functional service provider cardiology clinical research unit globalcode contract research organization technology small biotech assays stroke research clinical data nanomaterials renal drug biomarker cmc analytical solutions crop studies precision medicine patient care covance labs regulatory affairs oncology crowdsourcing oligonucleotides eudravigilance commercialization inflammatory bowel disease contract research site selection pharma case study immunotoxicology evidence data management oral toxicity studies study patient outcomes clinical fsp pharmacology crop testing biosimilar cmc analytical solutions patient focus patients clinical trial case study toxic substances control act (tsca) safety & risk management scientific posters toxicity study real-world data asset management immune mediated inflammatory diseases covance inc. marketplace fsp echa carcinogens alzheimers research eemgs clinical analytics biosimilar cmc in vitro genotoxicants alzheimers studies alzheimers disease biotherapeutics dna elisa biosimilar development bebpa wbs testing biological matrices lc-ms/ms cpt31 hiv parkinsons trials parkinson's disease clinically isolated syndrome patient retention ms studies multiple sclerosis neuroscience acute ischemic stroke ais trials ais studies observational research rbm risk based monitoring stroke case study phase ii drug development late-stage research spinal cord injury spinal cord study drug discovery genotoxins biosimilarity non-dna targets micronucleus assay microbiology startup drug device new drug global timeline consideration market entry imid regulations ulcerative colitis optimization disease phase iii drug development skin forecast innovation analysis digital non-alcoholic steatohepatitis general tox nonclinical pathology immunology infographic development models asset value infectious disease clinical devleopment ibd cystic fibrosis ra stem cells diabetes & endocrinology cvmer communication niemann-pick disease new compound investment cmc drug testing drug journey clinical trial enrollment r&d research life sciences early clinical development integration onlcology patient solutions clinical trial support patient service center machine learning health tech clinical trial testing covance biotech experience vendor management abuse liability drug abuse drug metabolism compliance interaction safety late phase herg testing lead optimization metid collaboration risk-based monitoring informatics quality clinical trial cost analytical development vaccine development renal drug development renal studies renal expertise diagnostics companion diagnostics real-time data bioa small molecule ra treatment bumblebee acute contact and oral toxicity studies toxicity pediatric clinical development pediatric medicines pediatric trials hybrid trials phase i hybrid trials reach requirements new product registration reach regulations european chemicals agency neonicotinoids chemical toxicology toxicology services pharmacology studies us toxic substances control act (tsca) reform k-reach legislation k-reach act on the registration and evaluation of chemical agriculture field trials agrochemical business plant protection products (ppps) inhalation study design dose calculation clinical application inhaled pharmaceuticals rodent inhalation study primates post approcal toxicology registration evaluation regulatory challenges ed regulatory framework endocrine disruptors (ed) us epa accelerator methodology oracle argus specialty pharma patient journey patient organizations phase i manufacturing habp trials vabp trials nash trials phase iv lab data management inhalation technology respiratory treatments covnace in vitro diagnostic product class iii medical device medical device development car-t clinical studies post-approval services post-approval solutions pv solutions biological medicines cancer chronic inflammatory diseases genetic disorders device development device development strategy genomics genome analysis gene expression mutational testing genotyping biobanking cdx scientific discovery global specimen solutions specimen lifecycle management biorepository chemical safety chemicals control act (cca) chemical accident prevention biocides biocide authorization data gap analysis risk protection plant metabolism studies oecd plant cultivation economic co-operation and development bee ecotoxicology studies ecotoxicology environmental protection authority (epa) eu regulations product value late phase development patient reimbursement new product launch cro partnership patient centric program scientific case study cro technology clinical trial participation investigator sites environmental risk assessment market approval cra randomized clinical trials rcts aph assay quality anatomic pathology histology clinical trial study design adalimumab mitra humira pharmacokinetic monoclonal antibody ema european medicines agency (ema) us fda medication european union science medical communications india medical affairs international pharmaceutical industry medical literature medical communication pharmacovigilance regulations medical literature monitoring (mlm) pharmacovigilance practices hcps health care professionals biocmc analytic methods clinical study design health economic communictions value proposition development patient data biomarker results specimen tracking chemistry manufacturing biosimilar strategy chemistry solutions safety & risk management support nonclinical data exchange validation automation data analytics johnson & johnson janssen send datasets send 3.1 focid validation opdivo client data keytruda biosimilars cmc clinical informatics xcellerate informatics suite cardiovascular protocol gastroenterology diabetes protocol patient populations neurology patient intelligence gdlh glutamate dehydrogenase aspartate aminotransferase (ast) alanine aminotransferase (alt) calprotectin inflammatory bowel disease (ibd) neutrophils troponin high sensitive (hs) assay ifcc microalbuminuria sdma renal function clinical data management biostatistics clinical monitoring oncology development phosphorodiamidate morpholino oligomer (pmo) clinical trial design liver disease pesticide risk market analysis social media safety data reporting adverse event (ae) pv automation molecule development product development mdt programmatic outsourcing ispor healthcare data drug packaging child-resistant packaging child safety f value pharma development fda critical path initiative critical path opportunity lis capillary gel electrophoresis nucleeic acid therapy emerging biotech cru ddi assessment ugt inhibition assays alzheimer's disease drug-drug interactions in vitro metabolic drug development china r&d center shanghai